Loading...
XNASAUPH
Market cap1.28bUSD
Dec 23, Last price  
8.95USD
1D
-0.89%
1Q
27.49%
Jan 2017
326.19%
Name

Aurinia Pharmaceuticals Inc

Chart & Performance

D1W1MN
XNAS:AUPH chart
P/E
—
P/S
7.30
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
11.06%
Rev. gr., 5y
227.90%
Revenues
176m
+30.95%
1,273,5621,177,8883,522,6492,334,6463,876,7464,052,1443,420,452927,5226,157,836948,561278,000235,000173,000420,000463,000318,00050,118,00045,605,000134,030,000175,513,000
Net income
-78m
L-27.88%
0000000000-16,647,000-18,607,000-23,295,000-70,792,000-64,120,000-123,846,000-102,680,000-180,966,000-108,180,000-78,020,000
CFO
-33m
L-57.93%
0000000000-16,904,000-17,766,000-18,713,000-41,169,000-51,610,000-63,456,000-69,858,000-157,692,000-79,529,000-33,461,000
Earnings
Feb 13, 2025

Profile

Aurinia Pharmaceuticals Inc., a clinical stage biopharmaceutical company, develops and commercializes therapies to treat various diseases in the United States and China. It is involved in developing voclosporin, an investigational drug for the treatment of lupus nephritis, dry eye syndrome, and focal segmental glomerulosclerosis. The company is headquartered in Victoria, Canada.
URL
https://www.auriniapharma.com
IPO date
Jul 16, 2001
Employees
300
Domiciled in
CA
Incorporated in
CA

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
175,513
30.95%
134,030
193.89%
45,605
-9.00%
Cost of revenue
258,825
247,023
223,668
Unusual Expense (Income)
NOPBT
(83,312)
(112,993)
(178,063)
NOPBT Margin
Operating Taxes
551
1,828
760
Tax Rate
NOPAT
(83,863)
(114,821)
(178,823)
Net income
(78,020)
-27.88%
(108,180)
-40.22%
(180,966)
76.24%
Dividends
Dividend yield
Proceeds from repurchase of equity
2,433
196,740
BB yield
-0.40%
-6.65%
Debt
Debt current
31,196
936
1,059
Long-term debt
179,616
15,240
16,419
Deferred revenue
Other long-term liabilities
10,911
12,166
15,950
Net debt
(139,878)
(373,214)
(448,600)
Cash flow
Cash from operating activities
(33,461)
(79,529)
(157,692)
CAPEX
(718)
(292)
(1,501)
Cash from investing activities
(6,706)
(60,632)
(103,870)
Cash from financing activities
(5,130)
2,433
221,112
FCF
(220,859)
(113,577)
(178,349)
Balance
Cash
350,489
389,390
466,078
Long term investments
201
Excess cash
341,914
382,688
463,798
Stockholders' equity
257,166
319,946
420,077
Invested Capital
244,904
105,118
82,889
ROIC
ROCE
EV
Common stock shares outstanding
143,236
141,915
129,369
Price
8.99
108.10%
4.32
-81.11%
22.87
65.37%
Market cap
1,287,692
110.04%
613,073
-79.28%
2,958,669
80.57%
EV
1,147,814
239,859
2,510,069
EBITDA
(71,665)
(110,287)
(175,302)
EV/EBITDA
Interest
2,775
5,118
Interest/NOPBT